Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents

Table 7

Adjusted expenditures.

		All-cause healthcare expenditures			Breast cancer-related expenditures
		Mean	Lower 95% CI	Upper 95% CI	Mean	Lower 95% CI	Upper 95% CI
HER2-targeted agent status
HER2-targeted agents	18,059	$11,107	$10,376	$11,838	$6,215	$5,734	$6,696
No HER2-targeted agents	18,059	$8,458	$8,266	$8,651	$3,908	$3,816	$4,000
No treatment	18,059	$8,284	$7,925	$8,642	$2,858	$2,713	$3,003
Incremental Expenditures; HER2-targeted agents; versus no HER2-targeted agents		$2,649	$1,892	$3,405	$2,307	$1,817	$2,796
Incremental Expenditures; HER2-targeted agents; versus no treatment		$2,824	$2,009	$3,638	$3,357	$2,855	$3,859
HER2-targeted agent patients
HT status
HT+	2,629	$10,359	$9,849	$10,869	$6,869	$6,487	$7,251
HT−	2,629	$12,924	$12,266	$13,582	$7,757	$7,317	$8,198
Incremental expenditures		($2,565)	($3,397)	($1,733)	($888)	($1,472)	($305)
De novo versus recurrent
De novo	2,629	$12,139	$11,438	$12,840	$8,200	$7,674	$8,726
Recurrent	2,629	$11,184	$10,689	$11,679	$6,791	$6,450	$7,131
Incremental expenditures		$955	$97	$1,813	$1,409	$782	$2,036
Age group
Age 18–44	2,629	$13,650	$12,670	$14,630	$9,075	$8,345	$9,806
Age 45–64	2,629	$13,101	$12,655	$13,547	$8,193	$7,878	$8,509
Age 65+	2,629	$8,570	$7,916	$9,224	$5,198	$4,744	$5,652
Incremental expenditures; Age 18–44 versus age 45–64		$549	($528)	$1,626	$882	$87	$1,678
Incremental expenditures; Age 65+ versus age 45–64		($4,531)	($5,323)	($3,739)	($2,995)	($3,548)	($2,443)